Preserving fertility when choosing chemotherapy regimens - the role of gonadotropin-releasing hormone agonists

被引:40
作者
Blumenfeld, Zeev [1 ]
Evron, Ayelet [2 ]
机构
[1] Technion Israel Inst Technol, Rappaport Fac Med, Rambam Hlth Care Campus, Reprod Endocrinol,Dept Obstet & Gynecol, IL-31096 Haifa, Israel
[2] Technion Israel Inst Technol, Rappaport Fac Med, Rambam Hlth Care Campus, IL-31096 Haifa, Israel
关键词
fertility preservation; gonadotropin-releasing hormone agonist; gonadotoxicity; premature ovarian failure; PREMATURE OVARIAN FAILURE; BREAST-CANCER PATIENTS; YOUNG-WOMEN; GNRH-AGONIST; PREMENOPAUSAL WOMEN; (NEO)ADJUVANT CHEMOTHERAPY; CELL TRANSPLANTATION; ORAL-CONTRACEPTIVES; PREGNANCY OUTCOMES; CHILDHOOD-CANCER;
D O I
10.1517/14656566.2015.1031654
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction: The late effects of cancer treatment have recently gained a worldwide ubiquitous interest among reproductive endocrinologists, oncologists, and all health care providers. Despite many publications on this subject, there are many equivocal issues necessitating summary. The case for and against using GnRH-agonist for fertility preservation is summarized with the rationale that preventing ovarian failure may be better than treating it. Areas covered: We searched Medline in the last 10 years using terms: 'fertility preservation', 'female chemotherapy', 'Gonadotropin-releasing hormone (GnRH) analogues', 'GnRH agonists' 'gonadotoxicity', and 'cancer treatment'. We included mainly publications from the past 7 years, but did not exclude previous, commonly referenced publications. Here, we summarize the various methods available for fertility preservation and minimizing chemotherapy induced gonadotoxicity. Expert opinion: Until now, 20 studies (15 retrospective and 5 randomized controlled trial) have reported on 2038 patients treated with GnRH-a in parallel to chemotherapy, showing a significant decrease in premature ovarian failure (POF) rate in survivors versus 8 studies reporting on 509 patients, with negative results. Patients treated with GnRH-a in parallel to chemotherapy preserved their cyclic ovarian function in 91% of cases as compared to 41% of controls, with a pregnancy rate of 19 - 71% in the treated patients. Furthermore, over 10 recent meta-analyses have concluded that GnRH-a are beneficial and may decrease the risk of POF in survivors. Because most of the methods involving ovarian or egg cryopreservation are not yet clinically established and unequivocally successful, these young patients deserve to be informed with all the various modalities to minimize gonadal damage and preserve ovarian function and future fertility. Combining the various modalities for a specific patient may increase the odds of preservation of future fertility.
引用
收藏
页码:1009 / 1020
页数:12
相关论文
共 88 条
[1]   Occasional involvement of the ovary in Ewing sarcoma [J].
Abir, Ronit ;
Feinmesser, Meora ;
Yaniv, Isaac ;
Fisch, Benjamin ;
Cohen, Ian J. ;
Ben-Haroush, Avi ;
Meirow, Dror ;
Felz, Carmela ;
Avigad, Smadar .
HUMAN REPRODUCTION, 2010, 25 (07) :1708-1712
[2]  
[Anonymous], AMERICAN SOCIETY OF
[3]  
[Anonymous], J ASSIST REPROD GENE
[4]   LUTEINIZING-HORMONE-RELEASING HORMONE AGONIST INHIBITS CYCLOPHOSPHAMIDE-INDUCED OVARIAN FOLLICULAR DEPLETION IN RHESUS-MONKEYS [J].
ATAYA, K ;
RAO, LV ;
LAWRENCE, E ;
KIMMEL, R .
BIOLOGY OF REPRODUCTION, 1995, 52 (02) :365-372
[5]   Assessment of ovarian reserve following ovarian tissue banking and/or GnRH-a co-treatment prior to chemotherapy in patients with Hodgkin's disease [J].
Azem, Foad ;
Samara, Nivin ;
Cohen, Tanya ;
Ben-Yosef, Dalit ;
Almog, Beni ;
Lessing, Joseph B. ;
Goor, Odeliya ;
Amit, Ami .
JOURNAL OF ASSISTED REPRODUCTION AND GENETICS, 2008, 25 (11-12) :535-538
[6]   RETRACTED: Gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage: prospective randomized study (Retracted article. See vol. 120, pg. 395, 2023) [J].
Badawy, Ahmed ;
Elnashar, Aboubakr ;
El-Ashry, Mohamed ;
Shahat, May .
FERTILITY AND STERILITY, 2009, 91 (03) :694-697
[7]   Gonadotropin-releasing hormone analog cotreatment for preservation of ovarian function during gonadotoxic chemotherapy: a systematic review and meta-analysis [J].
Bedaiwy, Mohamed A. ;
Abou-Setta, Ahmed M. ;
Desai, Nina ;
Hurd, William ;
Starks, David ;
El-Nashar, Sherif A. ;
Al-Inany, Hesham G. ;
Falcone, Tommaso .
FERTILITY AND STERILITY, 2011, 95 (03) :906-U94
[8]   Fertility and gonadal function in female survivors after treatment of early unfavorable Hodgkin lymphoma (HL) within the German Hodgkin Study Group HD14 trial [J].
Behringer, K. ;
Thielen, I. ;
Mueller, H. ;
Goergen, H. ;
Eibl, A. D. ;
Rosenbrock, J. ;
Halbsguth, T. ;
Eichenauer, D. A. ;
Fuchs, M. ;
Reiners, K. S. ;
Renno, J. H. ;
van der Ven, K. ;
Kuehr, M. ;
von Wolff, M. ;
Diehl, V. ;
Engert, A. ;
Borchmann, P. .
ANNALS OF ONCOLOGY, 2012, 23 (07) :1818-1825
[9]   No protection of the ovarian follicle pool with the use of GnRH-analogues or oral contraceptives in young women treated with escalated BEACOPP for advanced-stage Hodgkin lymphoma. Final results of a phase II trial from the German Hodgkin Study Group [J].
Behringer, K. ;
Wildt, L. ;
Mueller, H. ;
Mattle, V. ;
Ganitis, P. ;
van den Hoonaard, B. ;
Ott, H. W. ;
Hofer, S. ;
Pluetschow, A. ;
Diehl, V. ;
Engert, A. ;
Borchmann, P. .
ANNALS OF ONCOLOGY, 2010, 21 (10) :2052-2060
[10]   Pharmacological interventions for fertility preservation during chemotherapy: a systematic review and meta-analysis [J].
Ben-Aharon, Irit ;
Gafter-Gvili, Anat ;
Leibovici, Leonard ;
Stemmer, Salomon M. .
BREAST CANCER RESEARCH AND TREATMENT, 2010, 122 (03) :803-811